Advertisement

Advertisement
Leukemia

Zanubrutinib vs Ibrutinib in Relapsed or Refractory CLL

In an interim analysis of the phase III ALPINE trial reported in the Journal of Clinical OncologyPeter Hillmen, MBChB, PhD, and colleagues found that zanubrutinib...

Supportive Care
Hematologic Malignancies

Study Examines Coping Strategies Used by Caregivers of Patients Undergoing Stem Cell Transplants

November is Caregiver Awareness Month, and timely findings from a study published by Amonoo et al in the journal Blood Advances suggested that, among caregivers...

Solid Tumors
Genomics/Genetics

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors

As reported in JAMA Oncology by Schram et al, the phase IIb tumor-agnostic JAVELIN BRCA/ATM trial has shown that the combination of avelumab and talazoparib...


Advertisement
Issues in Oncology

Patients Who Are HIV-Positive and Have Cancer May Have Accelerated Epigenetic Aging

Patients with cancer who are living with the human immunodeficiency virus (HIV) infection had an increased epigenetic age compared with...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Kidney Cancer

Robert J. Motzer, MD, on RCC: Quality of Life for Patients Treated With Lenvatinib-Based Therapy vs Sunitinib

Breast Cancer
Genomics/Genetics

OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer

One year of adjuvant therapy with the PARP inhibitor olaparib extended disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer with BRCA1/2 germline mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented by Andrew Tutt, MB ...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Hepatobiliary Cancer

Lipika Goyal, MD, on Treating Intrahepatic Cholangiocarcinoma With Futibatinib

Breast Cancer
Genomics/Genetics

Are There Differences in the Prevalence of Germline Pathogenic Variants in Susceptibility Genes in Black vs White Women With Breast Cancer?

In a population-based study reported in JAMA Oncology, Susan M. Domchek, MD, and colleagues found “no clinically meaningful differences” in the prevalence of germline pathogenic variants in 12 established breast cancer susceptibility genes between Black and non-Hispanic White women with breast...

Breast Cancer
Survivorship

Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Who Received Chest Radiation

In an analysis from the Childhood Cancer Survivor Study (CCSS) and the Dutch Hodgkin Late Effects and LATER cohorts reported in the Journal of Clinical Oncology, Moskowitz et al developed a model for predicting the risk of breast cancer among childhood cancer survivors treated with chest...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Issues in Oncology
Health-Care Policy
Legislation

Jingxuan Zhao, MPH, on How Medicaid Expansion Affects Long-Term Cancer Survival

Bladder Cancer
Immunotherapy

KEYNOTE-361: First-Line Pembrolizumab With or Without Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Carcinoma

As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, the phase III KEYNOTE-361 trial has shown no significant improvement in progression-free or overall survival with first-line pembrolizumab plus platinum-based chemotherapy vs chemotherapy alone in patients with advanced...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...